Loading…
← CockpitCompetitor Analysis › 002880.SZ Shenzhen Weiguang Biological Products Co., Ltd. Class AOpen in the cockpit ↗

Shenzhen Weiguang Biological Products Co., Ltd. Class A002880.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology
Momentum neutral 59
Mkt cap
$633M
US dollars, full cap
Free float
22%
of shares outstanding
$/day
$3.79M
20-day average traded
Fwd P/E
19.2×
forward earnings
ROIC−WACC
+2.1 pp
WACC 5.3%
Hurdle
n/a
no reverse DCF
Next earnings
161 days
28 Apr 2027
Close · CNYCN¥18.87
1D-0.7%
1W-5.5%
1M-7.2%
3M-10.3%
6M-26.8%
YTD-26.0%
1Y-31.0%
ATR %3.1%
52w lowhigh44.2% off high

What Shenzhen Weiguang Biological Products does

Employees: 901

Shenzhen Weiguang Biological Products at a glance

Size Shenzhen Weiguang Biological Products (002880.SZ) is a China Health Care company (Biotechnology) with a market value of $633M, the 3122nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥18.87 on 18 Nov 2026.

Performance Over six months the shares fell 26.8%, against -12.9% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 20 in its peer set.

Growth Revenue fell 0.4% over the last twelve months (peer median +23.1%); the operating margin is 17.9% (peer median -130.4%).

Valuation It trades at 19.2× forward earnings against a peer median of 24.0× (2nd cheapest of 6).

Capital Return on invested capital runs 2.1 points above its cost of capital (5.3% WACC).

Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 87002880.SZ 74
Six months, rebased to 100: Shenzhen Weiguang Biological Products against the median of its 20 peers (local-currency closes).

Shenzhen Weiguang Biological Products financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.13BCN¥1.26BCN¥1.20BCN¥1.04BCN¥665M
Revenue growth—+5%+15%+57%—
Gross profitCN¥502MCN¥468MCN¥480MCN¥413MCN¥225M
EBITDAn/aCN¥445MCN¥439MCN¥328MCN¥176M
Net incomeCN¥170MCN¥246MCN¥254MCN¥219MCN¥118M
Free cash flow-CN¥69.4MCN¥108M-CN¥75.6MCN¥69.1M-CN¥325M
Capital expenditureCN¥108MCN¥170MCN¥256MCN¥329MCN¥327M
Total debtCN¥833MCN¥864MCN¥697MCN¥525MCN¥547M

Quarterly statements and history in the cockpit →

Shenzhen Weiguang Biological Products competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+500%+1,000%0%+50%JANXGERN603387688197688221SRZN68863999667729GNFTATTO002880.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Shenzhen Weiguang Biological Products is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×200×400×GERN6886399966GNFT300404002880.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shenzhen Weiguang Biological Products is the large dot.

Shenzhen Weiguang Biological Products competitors and peer comparison

How Shenzhen Weiguang Biological Products compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shenzhen Weiguang Biological Products against its 20 peers (data as of 18 Nov 2026)
Measure002880.SZPeer medianRank in peer set
1-month return-7.2%-13.1%9th highest of 21
6-month return-26.8%-12.9%7th lowest of 20
Distance from 52-week high-44.2%-44.6%9th highest of 21
Revenue growth (TTM)-0.4%+23.1%5th lowest of 17
Operating margin17.9%-130.4%2nd highest of 18
Forward P/E19.2×24.0×2nd cheapest of 6
ROIC minus cost of capital+2.1 pp-15.1 pp2nd highest of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shenzhen Weiguang Biological Products 002880.SZChina$633M-27%0%18%19.2×n/an/a
Janux Therapeutics JANXUnited States$631M-28%+133%-599%n/an/an/a
Geron GERNUnited States$638M-21%+19%-8%17.4×n/an/a
Getein Biotech 603387.SSChina$625M-13%+8%21%n/a-8.9%-1.3%
Shouyao Holdings Beijing 688197.SSChina$653M-26%+4,564%-92%n/an/an/a
Frontier Biotechnologies 688221.SSChina$658M-48%+153%-20%n/a40.3%+21.5%
Design Therapeutics DSGNUnited States$606M-15%n/an/an/an/an/a
Surrozen SRZNUnited States$605M+17%+192%-485%n/an/an/a
Anhui Huaheng Biotechnology 688639.SSChina$605M-45%+7%3%22.3×n/an/a
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%24.0×n/an/a
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Alebund Pharmaceuticals (Jiangsu) 9637.HKHong Kong$595Mn/a+674%-495%n/an/an/a
Kura Oncology KURAUnited States$674M-29%-24%-394%n/an/an/a
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$684M+74%-15%-8%n/a44.8%+14.7%
4D Molecular Therapeutics FDMTUnited States$578M+23%+79,952%-226%n/an/an/a
Prime Medicine PRMEUnited States$695M+35%+18%-2,584%n/an/an/a
Ascletis Pharma 1672.HKHong Kong$571M-72%-59%-71,976%n/an/an/a
Genfit GNFT.PAFrance$571M+22%+28%-130%431.5×39.8%+143.5%
Solid Biosciences SLDBUnited States$709M-2%n/an/an/an/an/a
Attovia Therapeutics ATTOUnited States$710M+1,325%n/a-5,945%n/an/an/a
Boji Medical Technology 300404.SZChina$561M-6%+32%4%69.3×31.9%+27.2%

Questions

Which companies are Shenzhen Weiguang Biological Products's closest peers?
The cockpit's peer set: Janux Therapeutics (JANX), Geron (GERN), Getein Biotech (603387.SS), Shouyao Holdings Beijing (688197.SS), Frontier Biotechnologies (688221.SS), Design Therapeutics (DSGN), Surrozen (SRZN), Anhui Huaheng Biotechnology (688639.SS).
Is Shenzhen Weiguang Biological Products expensive compared with its peers?
On forward p/e it trades at 19.2× against a peer median of 24.0×, 2nd cheapest of 6 in its peer set.
How has Shenzhen Weiguang Biological Products stock performed?
Over six months to 18 Nov 2026 the shares returned -26.8% against -12.9% for the median peer; over one year -31.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.